Key Reports in Lymphoma CAR T Therapies From ASH 2021

David Miklos, MD


January 06, 2022

Dr David Miklos, of Stanford University, reports on results of three of the most talked-about studies on CAR T-cell therapy in patients with large B-cell lymphoma (LBCL) as presented at this year’s American Society of Hematology annual meeting.

Dr Miklos begins with side-by-side comparisons of the trial schema and promising event-free survival outcomes of the ZUMA-7 and TRANSFORM studies.

He then offers his take on why study design differences led to positive outcomes for LBCL in the axi-cel and liso-cel arms of ZUMA-7 and TRANSFORM, respectively, but a negative outcome for patients with LBCL in the tisa-cel arm of the BELINDA study. All therapies targeted CD19, and all studies shared the aim of moving CAR T-cell therapies from standard-of-care third-line to second-line.

Finally, Dr Miklos discusses therapies that may receive FDA approval and changing approaches to salvage therapy for patients with relapsed and refractory LBCL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.